Janssen Says ViiV Submits SNDA for Expanded Use of Cabenuva
By Michael Dabaie
Johnson & Johnson's Janssen Pharmaceutical Co. said ViiV
Healthcare submitted a supplemental new drug application to the
U.S. Food and Drug Administration for the expanded use of
Cabenuva consists of Janssen's rilpivirine and ViiV Healthcare's
cabotegravir. The sNDA seeks to expand the Cabenuva label to
include administration every two months for the treatment of HIV-1
infection in virologically suppressed adults.
The FDA approved Cabenuva in January as a once-monthly,
long-acting regimen for the treatment of HIV-1 infection in
virologically suppressed adults. The regimen was co-developed as
part of a collaboration with ViiV Healthcare.
Write to Michael Dabaie at firstname.lastname@example.org
(END) Dow Jones Newswires
February 24, 2021 15:08 ET (20:08 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.